Barcelona Alzheimer Treatment & Research Center

Posts Tagged 2011

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2-Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia Alzheimer’s Disease Study.

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2-Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia Alzheimer’s Disease Study. Sikkes SA, Visser PJ, Knol DL, de Lange-de Klerk ES, Tsolaki M, Frisoni GB, Nobili F, Spiru L, Rigaud AS,






No evidence of APP point mutations and locus duplication in individuals with cerebral amyloid angiopathy.

No evidence of APP point mutations and locus duplication in individuals with cerebral amyloid angiopathy. Domingues-Montanari S, Parés M, Hernández-Guillamon M, Fernández-Cadenas I, Mendioroz M, Ortega G, Boada M, Masjuan J, Huertas N, Alvarez-Sabín J, Delgado P, Montaner J; Stroke Project of Cerebrovascular Diseases Study Group, Spanish Society






Evaluación de la conveniencia del cambio de vía de administración de Rivastigmina en pacientes con enfermedad de Alzheimer.

Evaluación de la conveniencia del cambio de vía de administración de Rivastigmina en pacientes con enfermedad de Alzheimer. Blesa R, Boada M, Martínez C, Gil-Saladié D, Antúnez C, Gobatt AL, Grupo KAPA..Neurologia.2011; 26 :262-71 – vol.26 núm 05 PDF






Genetic association of CR1 polymorphism rs3818361 in Alzheimer’s disease.

Genetic association of CR1 polymorphism rs3818361 in Alzheimer’s disease. Antúnez C , Boada M, López-Arrieta J, Moreno-Rey C, Hernández I, Marín J, Gayán J, González-Pérez A, Real LM, Alegret M, Tárraga L, Ramírez-Lorca R, Ruiz A, and the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2011 Jul;7(4):e124-9.






The MTHFD1L gene rs11754661 marker is not associated with Alzheimer’s disease: evidence from a sample of the Spanish population.

The MTHFD1L gene rs11754661 marker is not associated with Alzheimer’s disease: evidence from a sample of the Spanish population. Ramírez-Lorca R, Boada M, Antúnez C, López-Arrieta J, Moreno-Rey,Hernández I,  Juan Marín J, Gayán J, González-Pérez A, Alegret M, Tárraga L, Real L.M.,  Ruiz A. J Alzheimers Dis. 2011 Jan;25(1):47-50. PDF ResearchGate






The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s Disease.

The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s Disease. Antúnez C, Boada M, González-Pérez A, Gayán J, Ramírez-Lorca R, Marín J, Hernández I, Moreno-Rey C, Morón FJ, López-Arrieta J, Mauleón A, Rosende-Roca M, Noguera-Perea F, Legaz-García A, Vivancos-Moreau L, Velasco J, Carrasco JM, Alegret M, Antequera-Torres






Clinical features and APOE genotype of pathologically proven early-onset Alzheimer’s disease.

Clinical features and APOE genotype of pathologically proven early-onset Alzheimer’s disease. Balasa M, Gelpi E, Antonell A, Rey MJ, Sánchez-Valle R, Molinuevo JL, Lladó A; Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group. Neurology 2011;76:1-1.






ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy.

ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Domingues-Montanari S, Hernandez-Guillamon M, Fernandez-Cadenas I, Mendioroz M, Boada M, Munuera J, Rovira A, Maisterra O, Parés M, Gutierrez M, Alvarez-Sabin J, Chacón P, Delgado P, Montaner J; Stroke Project Cerebrovascular Diseases Study Group, Spanish Society of






2011 3133K1-3000-WW / 3133K1-3001-WW

Estudio: Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos en fase III para evaluar la eficacia y la seguridad de Bapineuzumab (AAB-001-ELN115727) en personas con la enfermedad del Alzheimer portadores de la apolipoproteína Eε4, en estado de moderado a grave. Código protocolo: 3133K1-3000-WW / 3133K1-3001-WW Promotor: Wyeth,






2011 H8A-MC-LZAN

Estudio: Efecto de la inmunización pasiva en la progresión de la enfermedad de Alzheimer LY2062430 versus placebo. Código protocolo: H8A-MC-LZAN Promotor: Lilly Fase: Fase III Enfermedad: Alzheimer (fase leve a moderada) Investigador principal: Mercè Boada Rovira Inicio: Octubre 2009 Estado: Activo, reclutamiento cerrado Final: Activo Monitorizado: 19 sujetos Incluidos: 19 sujetos Eficacia






Página 1 de 212